Evidence map›Paper›PMID 25775089›Full record

ArticlePloS one2015

Visualization by high resolution immunoelectron microscopy of the transient receptor potential vanilloid-1 at inhibitory synapses of the mouse dentate gyrus.

Miren-Josune Canduela, Juan Mendizabal-Zubiaga, Nagore Puente, Leire Reguero, Izaskun Elezgarai, Almudena Ramos-Uriarte, Inmaculada Gerrikagoitia, Pedro Grandes

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Insights into Potential Targets for Therapeutic Intervention in Epilepsy.International journal of molecular sciences · 2020
    Review
  4. Suppression of Presynaptic Glutamate Release by Postsynaptic Metabotropic NMDA Receptor Signalling to Pannexin-1.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
    Article
  5. Article
  6. Review
  7. The endocannabinoid system as a target for novel anxiolytic drugs.Neuroscience and biobehavioral reviews · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Miren-Josune CanduelaDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Juan Mendizabal-ZubiagaDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Nagore PuenteDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Leire RegueroDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Izaskun ElezgaraiDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Almudena Ramos-UriarteDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Inmaculada GerrikagoitiaDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Pedro GrandesDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, E-48940, Leioa, Spain; Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain.
Euskadiko Parke Teknologikoa · ESAchucarro Basque Center for Neuroscience · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have recently shown that the transient receptor potential vanilloid type 1 (TRPV1), a non-selective cation channel in the peripheral and central nervous system, is localized at postsynaptic sites of the excitatory perforant path synapses in the hippocampal dentate molecular layer (ML). In the present work, we have studied the distribution of TRPV1 at inhibitory synapses in the ML. With this aim, a preembedding immunogold method for high resolution electron microscopy was applied to mouse hippocampus. About 30% of the inhibitory synapses in the ML are TRPV1 immunopositive, which is mostly localized perisynaptically (∼60% of total immunoparticles) at postsynaptic dendritic membranes receiving symmetric synapses in the inner 1/3 of the layer. This TRPV1 pattern distribution is not observed in the ML of TRPV1 knock-out mice. These findings extend the knowledge of the subcellular localization of TRPV1 to inhibitory synapses of the dentate molecular layer where the channel, in addition to excitatory synapses, is present.

Indexed as

AnimalsCell BodyDendritesDentate GyrusFemaleGene Knockout TechniquesInhibitory Postsynaptic PotentialsMaleMiceMicroscopy, ImmunoelectronSynapsesTRPV Cation ChannelsTRPV1 protein, mouseTRPV Cation Channels

Identifiers

PMID25775089
PMCPMC4361705
OpenAlexW1977016175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.